Back to top
more

AZURRX BIOPHARM (AZRX)

(Delayed Data from NSDQ)

$2.55 USD

2.55
68,693

+0.05 (2.11%)

Updated May 3, 2019 03:59 PM ET

After-Market: $2.53 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Entero Therapeutics, Inc. [AZRX]

Reports for Purchase

Showing records 61 - 80 ( 134 total )

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 61

04/02/2020

Company Report

Pages: 5

Fortifies Its Cash Position Over 1Q20 - Reports 2019 Results

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 10.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 62

04/02/2020

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 63

04/01/2020

Company Report

Pages: 6

2019 Financial Results Reported; Reiterate Buy; Lowering PT to $2

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 64

03/03/2020

Company Report

Pages: 9

Capital - Catalysts

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 65

02/27/2020

Industry Report

Pages: 7

32nd Annual Conference: Jonathan Aschoff''s Biotechnology Track Overview

Provider: Roth Capital Partners, Inc.

Analyst: ASCHOFF J

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 66

01/24/2020

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 67

01/24/2020

Company Report

Pages: 10

We are transferring coverage

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 68

01/17/2020

Daily Note

Pages: 3

Transferring Coverage Update - Biotechnology Sector

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 69

01/10/2020

Company Report

Pages: 6

Phase 2 MS1819 Combo Study Interim Data to Be Presented; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 70

11/20/2019

Company Report

Pages: 9

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 71

11/19/2019

Company Report

Pages: 6

3Q19 Financial Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 72

10/18/2019

Company Report

Pages: 6

Cystic Fibrosis Foundation Gives Positive Opinion on MS1819; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 73

10/16/2019

Company Report

Pages: 6

First Patients Dosed in MS1819 Combo Study Enrolling Cystic Fibrosis Patients; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 74

10/15/2019

Company Report

Pages: 9

First Patient (Cystic Fibrosis) with EP is Dosed

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 75

10/11/2019

Company Report

Pages: 6

New President and Chief Executive Officer Appointed; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 76

09/26/2019

Daily Note

Pages: 5

Phase 2 Data Checks All the Boxes

Provider: Roth Capital Partners, Inc.

Analyst: ISAACSON J

Price: 10.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 77

09/26/2019

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 78

09/26/2019

Company Report

Pages: 6

Phase 2 Data in Cystic Fibrosis Warrant Further Study With Higher Dose

Provider: H.C. Wainwright & Co., Inc.

Analyst: CHEN Y

Price: 25.00

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 79

09/26/2019

Company Report

Pages: 7

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Entero Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 80

09/25/2019

Company Report

Pages: 9

A Belts - Suspenders Approach

Provider: DAWSON JAMES SECURITIES, INC.

Analyst: KOLBERT J

Price: 25.00

Research Provided by a Third Party
// eof